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Disorders of sex development (DSD) are rare disorders in which there is
discordance between chromosomal, gonadal, and phenotypic sex. Only a
minority of patients clinically diagnosed with DSD obtains a molecular
diagnosis, leaving a large gap in our understanding of the prevalence,
management, and outcomes in affected patients. We created a novel
DSD-genetic diagnostic tool, in which sex development genes are captured
using RNA probes and undergo massively parallel sequencing. In the pilot
group of 14 patients, we determined sex chromosome dosage, copy
number variation, and gene mutations. In the patients with a known
genetic diagnosis (obtained either on a clinical or research basis), this test
identified the molecular cause in 100% (7/7) of patients. In patients in
whom no molecular diagnosis had been made, this tool identified a genetic
diagnosis in two of seven patients. Targeted sequencing of genes
representing a specific spectrum of disorders can result in a higher rate of
genetic diagnoses than current diagnostic approaches. Our DSD diagnostic
tool provides for first time, in a single blood test, a comprehensive genetic
diagnosis in patients presenting with a wide range of urogenital anomalies.
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Disorders of sex development (DSD) are defined as
a rare set of conditions in which the chromosomal,
gonadal, and phenotypic sex is atypical. DSD has a
prevalence of 0.1–0.5% of live births, yet only 13% of
patients will ever receive a definitive genetic diagnosis
(this percentage is based on a systematic electronic
medical chart review targeting patients categorized
as DSD at one major mid-western academic medical
center) (1, 2). The uncertainty regarding the child’s
gender and future psychosocial and psychosexual
development is extraordinarily stressful for the child’s
family (1, 3, 4). From the time of initial presentation,
patients with DSD undergo a wide spectrum of clinical
and endocrine tests, from which life-altering decisions
are made about gender assignment, medical treatments,
and surgery. Yet, to date, evidence is lacking to justify
support for specific management strategies of these
patients (5).
The promise of next-generation sequencing in the
clinical arena is hindered by the difficulty in differen-
tiating between an inconsequential sequence polymor-
phism and a disease-causing mutation. Although the
first predictive test for BRCA1 and BRCA2 mutations
had numerous detractors, genetic testing for BRCA1 and
BRCA2 has transformed the management of high-risk
patients and in the process, researchers have discovered
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a vast number of gene variants, which are now classified
based on their cancer risk (6, 7).
Unlike traditional genetic diagnostic tests that at most
sequence a handful of genes or target a panel of known
mutations, we have combined multiple genetic tests and
put forward a novel and integrated role for comprehen-
sive molecular genetic diagnostics in the clinical realm.
Our test combines multiple genetic testing modalities
routinely ordered in DSD patients, including sex chro-
mosome complement determination, copy number vari-
ant (CNV) analysis, and gene sequencing. Currently,
gene sequencing is done on a gene-by-gene basis. Many
genes, particular those for rare or complex disorders, are
only offered on a research basis, further complicating
the genetic diagnostic process. This strategy replaces
multiple single-gene sequencing tests with a unified
test, thereby drastically improving the odds of iden-
tifying a high-risk variant and of assigning the appro-
priate management based on the individual’s genetic
risk.
We propose a novel diagnostic process allowing
clinicians to initially identify a genetic mutation, which
would be followed by relevant metabolic, endocrine,
and imaging tests for functional assessment of the gene
mutation. This diagnostic approach can eliminate non-
indicated clinical tests, sparing the patient unnecessary
stress and saving healthcare system’s resources. Finally,
by pinpointing the genetic diagnosis at the beginning of
the diagnostic process, we can more accurately analyze
and predict both future developmental issues in the
child and the risk of recurrence within the family.
In our pilot group of patients, we have shown that
this novel targeted diagnostic approach can accurately
diagnose the genetic basis of DSD in the majority
of patients. This new test shifts the paradigm of the
diagnostic processes and ultimately has the potential
to increase the rate of genetic diagnosis, provide more
cost-effective care, and allow for more informed clinical
management in patients with DSD.
Materials and methods
Clinical diagnosis of all DSD patients is outlined in
Table 1 and clinical features are described in detail
in Appendix S1. Patients with known genetic diag-
noses were diagnosed in either clinical laboratories or
on a research basis. Patients 45, X and 47, XXY,
and DSDPt7 were diagnosed in a clinical laboratory
using karyotype and/or Sanger sequencing. DSDPts 2,
3, 8 and 9 were genetically diagnosed on a research
basis only after extensive endocrine work-up. All other
patients did not have a genetic diagnosis. The clini-
cal and genetic diagnoses were blinded to the inves-
tigators. This study was approved by the Institu-
tional Review Board at the University of California,
Los Angeles. Capture was performed using custom
Sure Select Target Enrichment System Kit (Agilent)
(8). We designed oligonucleotide baits tiled against
exonic and intronic regions of 35 known genes of
sex development, up to 10 kb regions upstream and
downstream of all known genes in sex development,
and 3–10 kb spaced every 10 Mb along the X- and
Y-chromosomes (Table S1A,B). All clinically associ-
ated genes reported in the literature (as of December
2009) in both sex determination and sex differentiation
were included. We also included a subset of genes for
ovarian insufficiency. Up to six custom bar-coded sam-
ples were pooled, captured with the baits designed for
Table 1. Clinical diagnosis of patients with DSDa
Identification Clinical diagnosis
Genetic diagnosis known
(Y/N)
Genetic diagnosis
identified by targeted
sequencing (Y/N)
46, XY male Control XY male – –
46, XX female Control XX female – –
47, XXY KS Klinefelter syndrome Y Y
45, XO TS Turner syndrome Y Y
DSDPt1 5-Alpha reductase deficiency N Y (SRD5A2, E200K)
DSDPt2 46, XY gonadal dysgenesis Y [NROB1 (DAX1) duplication] Y
DSDPt3 46, XY gonadal dysgenesis Y (SRY, Y127C) Y
DSDPt4 46, XY gonadal dysgenesis + campomelic
dysplasia
N N
DSDPt5 46, XY gonadal dysgenesis + galactosemia N N
DSDPt6 46, XX testicular DSD N N
DSDPt7 46, XY DSD Y (AR, M788T) Y
DSDPt8 46, XY female + AHC Y (DAX1, Y121*) Y
DSDPt9 46, XY DSD severe combined adrenal and
gonadal deficiency
Y (CYP11A1) Y
DSDPt10 46, XX testicular DSD N N
DSDPt11 46, XY gonadal dysgenesis N N
DSDPt12 46, XY gonadal dysgenesis N Y (ATRX, K1045E)
AHC, adrenal hypoplasia congenita; DSD, disorders of sex development; N, no; Y, yes.
aAll patients in this study were clinically diagnosed with a DSD.
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one reaction and sequenced on a single lane of Illu-
mina GAIIx for 76 cycles or HiSeq2000 for 50 cycles.
The reads were aligned to the whole genome using
Novoalign (http://www.novocraft.com/index.html) and
the aligned reads were processed using sam tools
(http://samtools.sourceforge.net/) and Picard (http://
picard.sourceforge.net/) (9) to remove potential poly-
merase chain reaction duplicates. Both single-nucleotide
variants (SNVs) and small insertions and deletions
(INDELs) within the captured coding exonic and splice-
site intervals of the DSD genes were called using sam
tools pileup tool and annotated using the SeqWare
project (http://seqware.sourceforge.net) (10). The SNVs
and INDELs were further filtered to include only
those resulting in non-synonymous nucleotide substitu-
tion, frameshift, in-frame INDELs, splice-site, or early-
termination mutations. Finally, in order to minimize the
risk of false-positive SNV findings, only the variants
called with SNV Phred score ≥30, total coverage ≥10×
and percent of non-reference call ≥15 were further ana-
lyzed (Fig. S1). All variants with coding consequences
were analyzed against the public Human Gene Muta-
tion Database (HGMD), dbSNP132 (common vari-
ants present at ≥1% frequency), and SNVs were run
through three independent protein pathogenicity pre-
dictors: Polyphen-2, sift, and Mutation Assessor
in order to determine whether they were likely to be
disease-causing (11–13). When used together, the three
independent in silico pathogenicity predictors have a
higher positive predictive value and any of the predic-
tors alone (14). If two of the three algorithms predicted
a tolerable/benign effect of the mutation this was con-
sidered ‘likely benign’. All bioinformatic analysis was
performed blinded to the patient’s chromosomal sex,
phenotype, and diagnosis.
SNV validation
To determine the accuracy of our sequencing pipeline,
we compared DSDPt12 to previously acquired Illumina
IM SNP Genotyping data. This array was run and ana-
lyzed as per manufacturer’s protocols at the Southern
California Genotyping Consortium and had a call rate
of 0.9963. Six hundred ninety one SNPs within the
targeted region were also genotyped on this array and
compared to our SNP and INDEL variant callers. Four
of 691 SNPs were discordant between the genotyp-
ing data and the Illumina Sequencing data, giving a
false-negative rate of 0.57%. These false negatives were
four SNVs that the genotyping data called heterozy-
gous while the sequencing data did not. Conversely, the
sequencing did not identify any SNVs at base positions
where the genotyping data did not call an SNV.
Sex chromosome dosage and CNV analysis
Our sex chromosome complement analysis comprised
of two normalization steps. First, we normalize for
differences in coverage levels because starkly differ-
ent coverage levels between samples is a common
issue, known to hinder CNV analysis of targeted
sequencing data (15). Second, we normalize the X- and
Y-chromosome coverage to the sample’s autosomes in
order to perform inter-sample comparisons.
More precisely, any sample whose depth of coverage
(DOC) was 0.5 standard deviation higher than the mean
DOC of all the samples was subjected to normalization
of the DOC by reanalyzing a randomly selected subset
of reads. Once the DOC was similar among all samples,
we further normalized the samples, by dividing the
mean DOC on the X and the Y chromosomes, Ci(chrX)
and Ci(chrY) respectively, with the mean DOC of the
patient’s autosomes, Ci(chrAut). Since there are two
copies of every autosome, and 0, 1, or 2 copies of
the X and Y chromosomes, the ratio derived (0, 0.5,
or 1) allows us to estimate the number of X and a Y
chromosome per sample.
After the relative ratio of sex chromosome to
autosome for each sample was calculated, samples
were grouped by their estimated karyotype: XX, XY,
XXY or XO. Two-sample t-test was used to assess the
significance of the separation between different copy
number groups: 1 vs 2 X chromosomes and 0 vs 1
Y chromosome. The X and the Y chromosomes were
tested separately as their copy number states can be
considered to be independent of each other’s.
The same approach was taken for the copy number
assessment of the DSD genes, except that instead of
taking the mean DOC of the chromosomes, the mean
DOC of each gene (G) was calculated [Ci(Gj )] and
normalized by dividing with the mean DOC of the
autosomes [Ci(chrAut)].
To detect CNVs at genic or exonic level for
sample i, gene Gj or exon Ej , the normalized
DOC Ci(Gj )/Ci(chrAut) or Ci(Ej )/Ci(chrAut), was
compared to those of the rest of the samples to
determine if it was significantly greater or less. For the
CNV analysis of the genes or the exons, outlier for each
gene was determined by assessing how the normalized
coverage of a sample is significantly different from the
rest of the samples. The Z-score of a known duplication
was used to determine the lower bound (LB) and upper
bound (UB) for each gene or exon and a gene or exon
falling outside the LB or UB was considered an outlier.
Results
Targeted sequencing achieved a capture efficiency of
∼51.5% and a mean coverage of ×48.3 per sample with
92.6% of the targeted base positions being sequenced
at ≥×10. A total of 16 individuals were sequenced
in our targeted approach, 2 unaffected individuals and
14 patients clinically diagnosed with DSD (Table 1).
Some of the targeted regions were not covered due
to the presence of repetitive regions, which comprised
2.3% of the total regions covered. Repetitive regions
are historically difficult to sequence and map back to
the reference genome and these findings are consistent
with previously published results of targeted sequencing
(8, 16). However, none of the genes sequenced are
known to have mutations dependent on the size of
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these repetitive regions. To estimate the rates of false-
positive and false-negative SNV calls, we compared
SNP genotyping data to our SNV and INDEL calls in
DSDPt12 and calculated a false-negative call rate of
<1% and found 0 false positives.
In order to analyze sex chromosome dosage, the nor-
malized DOCs for both chromosomes, Ci(chrX)/Ci(chr-
Aut) and Ci(chrY)/Ci(chrAut), were calculated and
independently examined (Fig. 1). First, we reliably dis-
tinguish between samples with one or two
X chromosomes (p < 0.001). Calling the number of Y
chromosomes was also clear as the four samples with no
Y chromosome had nearly null coverage while the 10
samples with Y chromosomes had close to half the cov-
erage compared to the (diploid) autosomes (p < 0.001).
Sample 47, XXY was properly clustered with the XX
samples on the x-axis and the XY samples on the y-
axis. Sample 45, X was properly clustered with the
XY samples on the x-axis and had null coverage on
the Y-chromosome. All of our called sex chromosome
dosage matched clinically performed cytogenetic kary-
otype tests.
To identify both rare and common variants that might
result in DSD, we employed a number of filters. First,
to identify variants previously identified in the literature
as causative of DSD we compared all coding SNVs
and INDELs against HGMD public, which includes
both rare and more ‘common’ causes of DSD. We then
filtered out common variants using dbSNP132 (≥1%
frequency) and then ran all novel variants through in
silico protein pathogenicity predictors to determine if
they were likely benign and causative (see Fig. S1).
An average of 30 SNVs and INDELs was called
along all coding exons ±3 bp and in the testis-specific
SOX9 enhancer (17) in each patient. Few variants led
to protein-level changes (frameshift, in-frame INDELs,
early-termination, missense, and splice-site) in each
sample. Of 19 high-quality protein-changing variants
in all patients, five were reported to be causal vari-
ants for a similar phenotype in the HGMD public ver-
sion (Table 2) (18). In the DSD patients without sex
chromosome abnormalities, four patients (DSDPts 3, 7,
8, and 9) had a previously identified genetic diagno-
sis, all of which were identified through screening of
HGMD. This approach also identified a genetic diag-
nosis of 5-alpha reductase deficiency in DSDPt1. None
of the mutations identified in HGMD were present in
dbSNP132 (≥1% frequency), indicating that these are
rare variants. Additionally, we also identified a genetic
mutation not present in HGMD public in DSDPt12,
which is described below.
Of the remaining 14 variants, six were found to
be common polymorphisms recorded in dbSNP132
(≥1% frequency), and therefore classified as likely
benign mutations. The remaining eight variants were
not present in dbSNP132 (≥1% frequency), indicating
Fig. 1. Sex chromosome complement. Depth of coverage (DOC) along the X- and Y-chromosomes was normalized to the autosomal DOC and
plotted to determine sex chromosome complement. All XY samples (upper left) clustered together and had normalized coverage ranging from 0.43
to 0.63 for the X-chromosome and 0.58 to 0.72 for the Y-chromosome. All XX samples (lower right) clustered together, had null Y-chromosome
coverage, and had close to 1 for normalized X-chromosome coverage, indicating an absence of the Y-chromosome and two copies of the X-
chromosome. An X marks the mean coverage for the 46, XY cluster or the 46, XX cluster. The p-values for separating the two clusters were
<0.001 for both directions, and DSDpt3 that had the highest DOC (0.63) along the X-chromosome was separated from the 46, XX cluster with a
p-value of <0.001.
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they were rare variants, thus potentially pathogenic.
Discerning between benign and potentially pathogenic
rare variants required a multistep approach.
INDELs that result in out-of-frame coding conse-
quences or lie in canonical splice junctions are auto-
matically classified as ‘likely pathogenic’ (19). A single
insertion disrupting a canonical splice-site found in
CYP11A1 for DSDPt9 was not identified in HGMD
or dbSNP132 (≥1% frequency). This was classified as
likely pathogenic and is concordant with the known
compound heterozygous genetic diagnosis in CYP11A1.
The remaining seven rare SNV variants were ana-
lyzed using two independent methods: (i) SNVs were
run through three in silico protein pathogenicity predic-
tion algorithms and (ii) SNVs were manually evaluated
based on inheritance of the disease (i.e. sex-limited,
recessive, dominant) and patient phenotype. These two
analyses ensured that we were not excessively filtering
out rare variants solely based on in silico pathogenic-
ity predictors. We opted to be more conservative in our
calling of benign variants, requiring that two of three
pathogenicity predictors predict a tolerable effect and
that the manual analysis did not find the SNV as likely
to be causative.
In DSDPt12, diagnosed with 46, XY gonadal dysge-
nesis, we identified one hemizygous K1045E mutation
in ATRX (20). One of the three pathogenicity predictors
called the missense mutation ‘probably damaging’ and
manual inspection identified SNV in ATRX as causative
in DSDPt12 with 46, XY gonadal dysgenesis. There-
fore, we called this a likely pathogenic mutation in the
patient. All other SNVs were called as benign or tol-
erable by two of the three predictors. When manually
evaluated, these same SNVs were either not pathogenic
because of inheritance (e.g. the gene typically requires
pathogenic mutations on both alleles to show a phe-
notype) and/or the phenotype was sex-limited and only
displayed in either XY or XX individuals. In combining
the data from in silico protein pathogenicity predictors
and manual evaluation, the remaining six SNVs were
classified as likely benign.
As duplication and deletions can contribute to DSD,
we screened all of our patients for causative DSD
duplications and deletions (21, 22). In DSDPt2, who
has an XY karyotype, the mean DOC of NROB1
(DAX1 ), CDSDpt2 (NROB1 ), was elevated to the level
of the mean coverage achieved by the samples with
XX karyotype (Fig. 2), indicating copy number increase
at the locus (21). The normalized coverage of NROB1
gene in DSDPt2 was 2.75 standard deviations away
(Z-score = 3.04) from the mean of the normalized
coverage of NROB1 of all XY samples (p = 0.002).
To call CNVs, we have chosen a significance threshold
of Z-score 3.04 away from the mean to call a deletion or
duplication involving an entire gene based on the results
from DSDPt2, which generates a false-positive rate for
CNVs of 0.1%. All other DSD genes were tested in
the same manner, with no additional duplications or
deletions identified (Appendix S1, Fig. S2).
Fig. 2. Copy number variant analysis. To determine CNV status for NROB1 (DAX1 ), coverage for each gene was normalized to autosomal coverage
of each sample and all samples plotted based on normalized coverage. Since NROB1 is an X-chromosome gene, normalized coverage was plotted
separately based on the X-chromosome karyotype. DSDpt2, with 46, XY GD, had significantly higher coverage than other XY individuals, indicating
a duplication of the gene (p = 0.002). An X indicates the mean coverage for the gene.
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Discussion
The proposed method of broad-scale sequencing of all
known DSD genes offers significant advantages over
current diagnostic procedures for the assessment of
DSD. The vast majority of disease-causing mutations
can be attributed to sequence and copy number
variations affecting the coding regions of genes.
We limited the targeted genes to those with known
roles in sex development, as pathogenic mutations
in these genes can be confidently reported back to
the clinician and patient. While we cannot identify
novel genes in sex development using this approach,
limiting the number of genes sequenced streamlines
the bioinformatic analysis and restricts the pathogenic
variants to those genes relevant to phenotype. Another
major advantage of this DSD-specific approach, rather
than whole-exome or whole-genome sequencing, is that
we decrease the chance of incidental findings unrelated
to DSD. For instance, we eliminate the possibility of
diagnosing minors with adult-onset diseases unrelated
to the reason for genetic testing. Genetic testing
for adult-onset diseases is ethically questionable in
children, and under current guidelines is only performed
in exceptional circumstances (23). However, because
the targeted method is readily scalable, inclusion of
novel sex development genes or expansion of the
targeted region to also include all genes resulting in
ovarian insufficiency or male infertility can be easily
updated in future capture designs.
Intensive study of important disease genes such as
CFTR and BRCA1/BRCA2 has taught us the complexity
of single-gene disorders. The vast majority of disease
genes show remarkable mutational heterogeneity in the
general population (as opposed to the more restricted
mutation sets found in certain ethnic groups), with
mutations scattered across all exons of the genes with
no particular ‘hot-spots’. In such situations, there is
really no alternative to whole-gene sequencing (at least
of the exons and intron–exon junctions) if one is
to entertain any hope of identifying the majority of
causative mutations in affected individuals. The current
price for full-gene sequencing of BRCA1 and BRCA2,
for example, is, at time of this writing, about $3600. The
price for other individual genes offered in the clinical
setting ranges from about $1500 to $3000, depending
on the exonic size and other factors such as overall
demand and test exclusivity. For those genetic disorders
caused by many different genes, such as DSD, the cost
of sequencing them is prohibitive and is rarely done.
The majority of the patients with congenital adrenal
hyperplasia, for example, have mutations in CYP21A2,
while a smaller proportion of patients with the same
condition have mutations in one of the four other
genes that give rise to similar phenotypes (24) (POR,
STAR, HSD3B2, CYP11B1, and CYP17A1 ). Sequencing
all six genes by current methods would cost over
$10,000. Assuming that we pool a minimum of
seven bar-coded samples for one reaction worth of
targeted baits and sequence on one lane of an Illumina
HiSeq2000 flow cell with 50-bp paired-end reads, our
comprehensive sequencing approach would cost less
than $1000 per sample. Included in this cost per sample
is the labor and reagents for library preparation ($350),
cost of targeted baits ($150), bioinformatic analysis
($200), and the full-sequencing service ($300). Even
with the additional costs that need to be factored
in if performed within a clinical setting, such as
hospital overhead, maintenance of CLIA, CAP and
state certifications, and the higher labor costs of
licensed medical technologists, the proposed method
would come out to be significantly cheaper while
providing more information than current one-gene-at-
a-time Sanger sequencing approaches. While endocrine
testing and radiological imaging can help to prioritize
the order in which genes are sequenced, these tests may
lengthen the diagnostic process, increase costs, and are
sometimes invasive. Sequencing all the genes upfront
requires only a blood draw, and the entire process can
be completed in less than 3 weeks, which is shorter
than the turnaround time for clinical molecular genetic
sequencing tests for single genes.
Several groups have explored similar targeted
sequencing approaches to encompass all known genes
conferring an inherited risk of breast/ovarian can-
cer, congenital ocular disorders, or hereditary hearing
loss (16, 25, 26). Both commercial and academic ref-
erence laboratories have realized the utility of such
panels, and now offer sequencing services for all genes
causing various cardiomyopathies, and other pheno-
typic traits associated with 20 or more genes (27). All
of these approaches simply replace the current one-
gene-at-a-time sequencing tests traditionally offered,
reducing the cost while increasing the diagnostic yield.
However, we have yet to see a systematic reevaluation
of the powerful role that such genetic diagnosis can
play in early diagnosis and management. By integrating
these diagnostic tools into the clinical framework, we
might eliminate unnecessary tests and the risks, costs,
and diagnostic delays associated with them. Further-
more, with the cost of whole-genome sequencing soon
falling below the aggregate cost of performing stan-
dard Sanger sequencing on two or three single genes,
it is likely that health care systems will be reluctant to
cover the latter, when much more comprehensive diag-
nostic information can be gained for the same price by
massively parallel sequencing.
The ability to provide a single test that produces
such a variety of genetic information (copy number
variation, sex chromosome complement, and sequence
variants) has the potential to significantly alter clinical
practice. In our cohort of 14 patients, a diagnosis was
identified in 9 of 14 (64%). Parents with children
afflicted with a genetic disease place a high value on
obtaining a genetic diagnosis, even with the knowledge
that a diagnosis is not reached in all cases and that
identification of the genetic lesion will not necessarily
affect medical management (28). By establishing a
primary genetic diagnosis, the patient is spared a long
and difficult diagnostic process including numerous
costly and sometimes invasive tests. For parents dealing
with the appreciably greater stress of a child presenting
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Fig. 3. Proposed integration of targeted sequencing approach to clinical management of suspected DSD. Current clinical management begins with
the identification of an abnormal phenotype and is followed by multiple metabolic and endocrine tests, genetic tests, and imaging studies in order to
identify the mostly likely candidate for sequencing. Targeted sequencing approach would prioritize a genetic diagnosis, which would be functionally
assayed and confirmed with endocrine and imaging studies of the patient.
with a DSD, a genetic test may provide a better
understanding of the condition’s etiology and outcomes.
The next step is to evaluate the impact of genomic
sequencing on quality of life in patients with rare
genetic disorders such as DSD.
Our novel results show the potential of using next-
generation sequencing to reframe the typical diagnosis
pipeline within clinical medicine. This is especially true
for those patients with rare disorders who have variable
phenotypes and multiple genes associated with the
phenotype, such as DSD. The development of clinical
diagnostic tools targeted toward broader phenotypes
will catapult molecular diagnostics from a confirmatory
test to a primary diagnostic tool that can diagnose and
triage the patient earlier into appropriate management.
Traditional clinical diagnosis for newborns present-
ing with atypical phenotypic sex requires karyotype
tests, electrolyte measurements, hormone challenges
and stimulation tests, and imaging studies to visual-
ize the gonads and internal reproductive structures.
For newborns presenting with ambiguous genitalia, the
major life-threatening concern is salt-wasting adrenal
crisis. Therefore, we propose that all newborns pre-
senting with ambiguous genitalia should be monitored
until it can be safely determined that there is no risk
of adrenal crisis. At the same time, in lieu of perform-
ing all the other subsequent clinical tests enumerated
above, we propose that a blood specimen be sent for
targeted DSD sequencing to identify the causative gene
mutation. Once the involved gene is identified, follow-
up functional tests can be performed to direct clinical
management (Fig. 3). Establishing a precise genetic eti-
ology early on allows one to predict the likelihood of
developmental delay as well as conditions that might
not be apparent in the newborn period.
The targeted approach is ideal for disorders that have
similar phenotypes, typically affecting a single organ
system, which can be the result of mutations in many
different genes. Rare cases that are not genetically
diagnosed by the targeted approach will require a
more comprehensive work-up to identify novel gene
variants, non-coding variants, or copy number changes.
However, these cases are the exception and not the
rule and we believe the targeted approach will provide
a diagnosis in the majority of DSD patients. Patients
in whom a targeted approach is unable to identify a
genetic cause of the DSD or patients with rare cases
of DSD that have not been associated with a gene,
such as agonadism, would be excellent candidates for
whole-exome and whole-genome approaches. Because
non-targeted approaches identify more novel variants,
both within coding and the non-coding regions, these
technologies can be more difficult to interpret clinically.
Next-generation sequencing has only begun to illumi-
nate the genetic variants responsible for rare Mendelian
diseases. As targeted sequencing approaches become
cheaper and generate more data, it is up to the medi-
cal community to create sophisticated tests to utilize the
technology such that physicians and patients can benefit
from this revolutionary technology.
Supporting Information
The following Supporting information is available for this article:
Fig. S1. Targeted sequencing diagnostic pipeline. Bar-coded
genomic DNA was pooled and captured to sequence 2.5 Mb of
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genomic DNA corresponding to the genes known to be important
in sex development. All data was aligned to the human reference
genome hg18 and then put through the subsequent bioinformatics
analysis to identify copy number variants and sequence variants
and estimate sex chromosome dosage.
Fig. S2. Copy number variant analysis for disorders of sex
development genes. We performed copy number variant analysis
on all known genes of sex development. Genes located on the X-
or Y-chromosome were separated based on the number of each sex
chromosome in the sample. For each autosomal gene, all samples
were analyzed together. No outliers were detected among these
samples (DAX1 with duplication is illustrated in Fig. 2).
Table S1. Captured genomic intervals. All targeted genomic
intervals are based on the reference genome hg18. (A) All
captured genomic intervals for 35 genes known to be important
in mammalian sex development. Both exonic and intronic regions
were captured for these regions. (B) For sex chromosome dosage
analysis, we captured regions along the X- and Y-chromosomes
spaced approximately 10 Mb apart.
Table S2. Sequencing quality statistics. For each sample, capture
specificity, mean coverage, and percent of targeted bases covered
by 10 or more reads are shown. After optimization, we were able
to pool six samples together (DSDPts 7–12), with higher on-target
rate (capture specificity >0.5) and sufficient coverage with majority
of the targeted bases covered at 10× or greater. Coverage for the
autosomes, X- and Y-chromosomes are given separately.
Appendix S1. Supplementary methods.
Additional Supporting information may be found in the online
version of this article.
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